- Briefing Your roundup of Asian tech and startup news that matter
Miguel Cordon · · 1 min readChinese drug discovery startup banks $147m in series C round
State-owned Shenzhen Investment Holdings, clinical contract research organization Hangzhou Tigermed, Beijing’s Huarong Rongde Asset Management, and private equity fund Sinopharm-CICC Capital participated in the round.
Other backers include CCB International, Hongtai Capital Holdings, Sealand Innovation, Infinity Group, Founder H Fund, and DNV Capital.
Founded in 2013, Hinova covers areas such as metabolic diseases and cancer. It currently has one new anti-prostate cancer drug in phase 3 of international multi-center trials, an anti-hyperuricemia and gout drug being developed in phase 1 clinical trials in China, as well as several projects in earlier stages.
On its website, the company said that it’s looking to onboard a chief financial officer with experience in IPOs in Hong Kong.
In July last year, the company completed a US$40 million series B round led by healthcare-focused private equity fund Hermed Capital and China’s Fosun Pharma. Hinova raised its series A round in 2017 from Haisco Pharmaceutical.
Editing by Collin Furtado and Jaclyn Teng
(And yes, we’re serious about ethics and transparency. More information here.)
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.
